ABIM Oncology with
complete verified solutions
2025-2026
premenopausal women > 35 with a 5-yr breast cancer risk of greater than
or equal to ____ should be treated with _________ - answer 1.7%, tamoxifen
women with BRCA1/2 mutations should begin breast cancer screening at
age ____ - answer 25
for invasive breast cancer (stage III/IV), breast-conserving treatment can
be considered for tumors less than or equal to ______ - answer 5 cm
surgery required for breast cancer involving skin or chest wall - answer
mastectomy
tamoxifen increases risk of this cancer - answer endometrial
neoadjuvant chemo is required for breast cancer stage - answer III (A to C;
tumor > 5 cm with lymph node involvement, skin/chest wall involvement,
and or extensive axillary lymph node involvement)
women with BRCA1/2 mutations or FH of Lynch/HNPCC should receive
ovarian ca screening starting at age ____ - answer 30
treatment for ovarian cancer confined to ovaries without high-risk
features (I) - answer surgery alone
treatment for ovarian cancer confined to ovaries with high-risk features (I)
- answer surgery followed by chemotherapy
complete verified solutions
2025-2026
premenopausal women > 35 with a 5-yr breast cancer risk of greater than
or equal to ____ should be treated with _________ - answer 1.7%, tamoxifen
women with BRCA1/2 mutations should begin breast cancer screening at
age ____ - answer 25
for invasive breast cancer (stage III/IV), breast-conserving treatment can
be considered for tumors less than or equal to ______ - answer 5 cm
surgery required for breast cancer involving skin or chest wall - answer
mastectomy
tamoxifen increases risk of this cancer - answer endometrial
neoadjuvant chemo is required for breast cancer stage - answer III (A to C;
tumor > 5 cm with lymph node involvement, skin/chest wall involvement,
and or extensive axillary lymph node involvement)
women with BRCA1/2 mutations or FH of Lynch/HNPCC should receive
ovarian ca screening starting at age ____ - answer 30
treatment for ovarian cancer confined to ovaries without high-risk
features (I) - answer surgery alone
treatment for ovarian cancer confined to ovaries with high-risk features (I)
- answer surgery followed by chemotherapy
